envelope graphic E-mail page  

leaf

Innovations in Pediatric Stem Cell Transplant Research

Clinical Trials Benefit Many Patients

The stem cell transplant physicians and researchers at the University of Chicago are at the “forefront of medicine” -- always looking for new and better ways to treat our patients and to improve the quality of life after treatment.

Researcher in lab

All of our transplant patients are treated with protocols that are part of institutional or national clinical trials -- research studies that look at transplant, infection, graft vs. host disease and other aspects of this treatment.

When your child is treated at the University of Chicago Medicine Comer Children’s Hospital, he or she benefits from previous and ongoing research studies. What we learn about your child will also help other patients in the future.

Innovations Expand Stem Cell Transplant Treatment

The teams of clinicians and researchers at Comer Children's Hospital and the Institute of Molecular Pediatric Sciences at the University of Chicago are combining clinical intervention, clinical research and laboratory investigation to explore more applications for stem cell transplantation and to improve the success rate of this promising treatment. Under the leadership of John Cunningham, MD, chief of the Section of Pediatric Hematology/Oncology, the multidisciplinary stem cell sciences program has a "bench to bedside" approach so that discoveries in the lab can be rapidly translated into clinical advances.

Some recent innovations in stem cell transplant include:

Cameron Dykstra Cameron is thriving after receiving stem cells from his father. » Read Cameron's story

Expanding the Donor Pool to Include Parents

Because parents represent only a 50 percent genetic match for their children, conventional methods of stem cell transplantation using parent donors result in high rates of infection and rejection. Dr. Cunningham's research has identified a unique approach to purify parent stem cells, isolating only what is needed for transplant. With this approach, researchers have seen a four- to five-fold reduction in severe graft vs. host disease.

Post-Transplant Therapy to Prevent Relapse

This complication remains a significant risk in our patients. We are one of the small number of institutions in the nation that provides an extensive array of post-transplant immunotherapy strategies including: infusion of donor lymphocytes; natural killer cell and mesenchymal stem cell infusions; and, in some instances, the use of post-transplant chemotherapy. These approaches are reinforced by University of Chicago Comprehensive Cancer Center research programs and by the University of Chicago Biological Sciences Division programs and departments. These programs are focused on the development of novel chemotherapeutic agents for use in transplantation in malignant diseases of childhood, the use of new approaches to purify cell populations with strong activity against malignant cells and the development of tumor vaccines.

Transplantation for Relapsed/Refractory Leukemia

We are particularly interested in identifying new approaches to transplant children with leukemia for whom conventional chemotherapy has failed to control their disease, have relapsed after an allogeneic stem cell transplant, or who have developed a secondary leukemia after being treated earlier in life for another malignancy. These studies are supported In part by a multi-million dollar award from the Cancer Research Foundation. Approaches currently being considered for these patients include the use of reduced-intensity therapies, the combination of mismatched related and cord blood grafts, and post-transplant Immunotherapy.

Transplantation for Non-Malignant Disease

The team has a long-term interest in developing effective and safe transplantation strategies for hemoglobinopathies and immunodeficiencies. (National awards and local philanthropy fund work in this area). Using new graft development strategies, the team offers novel strategies for sickle cell anemia and β-thalassemia, bone marrow failure syndromes and metabolic storage diseases. Given the high degree of multi-organ involvement in these conditions, this treatment is supported by internationally known, multidisciplinary experts at Comer Children's Hospital. These experts are focused on the critical care, pulmonology, genetics, and cardiovascular complications associated with effective therapy of these conditions.

Advances in Stem Cell Biology

The Center for Stem Cell Biology and Regenerative Medicine at the University of Chicago focuses on enhancing our understanding of the role of stem cells in all organs, and using this information to develop new cellular therapies to treat devastating diseases of childhood. As a leader of this initiative, Dr. Cunningham and his team have immediate access to this information, and use it to advance patient care expeditiously. The success of these endeavors has been recognized with several awards from national and local philanthropic foundations.


Appointments

Or call 1-888-824-0200

Video



View a video about a grant that supports important University of Chicago research into combating therapy-related leukemia, a secondary cancer that develops in approximately 10 percent of patients who are treated for cancer.

Contact Us

Contact our program at (773) 702-6808



MyChart | CareLink | Notice of Privacy Practices | Financial Assistance | Legal Disclaimer | JCAHO Public Notice | Contact Us | Site Map

The University of Chicago Medicine Comer Children's Hospital  |   5721 S. Maryland Avenue   |   Chicago, IL 60637